MedTrace Logo

Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer

NCT03214939 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-07-12

No results posted yet for this study

Summary

The purpose of this work: to assess the tolerability and effectiveness of the autogemotherapy method on the basis of autologous antigen-activated dendritic cells in the treatment of patients with colorectal cancer.

This technology is intended for complex treatment of patients with colorectal cancer and is aimed at preventing the occurrence and treatment of secondary foci. The need for this technology is justified by the widespread occurrence of colorectal cancer, a decrease in the average age at onset of the disease, and the chemoresistantness of locally advanced forms of cancer.

Conditions

Interventions

BIOLOGICAL

Immunotherapy based on dendritic cells

Intravenous injection of cells

Sponsors & Collaborators

  • Research Institute of Fundamental and Clinical Immunology

    lead OTHER_GOV

Principal Investigators

  • Sergey V. Sennikov, MD · RIFCI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-27
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03214939 on ClinicalTrials.gov